This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reszka, K. J. Articles by Burns, C. P. Search for Related Content PubMed PubMed Citation Articles by Reszka, K. J. Articles by Burns, C. P.

Inactivation of Anthracyclines by Cellular Peroxidase

¹ Research Service and Department of Internal Medicine, The Veterans Affairs Medical Center; Departments of ² Medicine and ³ Radiation Oncology (Free Radical and Radiation Biology Graduate Program), and ⁴ Molecular Analysis Facility, Roy J. and Lucille A. Carver College of Medicine, and Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa

Requests for reprints: C. Patrick Burns, Department of Medicine, University of Iowa Hospitals, Iowa City, IA 52242. Phone: 319-356-2038; Fax: 319-353-8383; E-mail: c-burns{at}uiowa.edu.

The anticancer anthracyclines, doxorubicin and daunorubicin, are highly cytotoxic to both cancer and normal cells. In this work, we have investigated the capacity of cellular myeloperoxidase to inactivate these agents. We show that incubation of human leukemia HL-60 cells with the anthracyclines in the presence of hydrogen peroxide and nitrite causes irreversible oxidation of the drugs, suggesting an extensive modification of their chromophores. Methimazole, 4-aminobenzoic acid hydrazide, or azide inhibits the reaction, suggesting that it is mediated by the cellular myeloperoxidase, an enzyme naturally present in large amounts in HL-60 cells. In contrast to the intact drugs, the oxidatively transformed anthracyclines were substantially less cytotoxic for HL-60 (assayed by apoptosis) and PC3 prostate cancer cells and H9c2 rat cardiac myoblasts in vitro (assayed by clonogenic survival), indicating that the oxidative metabolism of these agents leads to their inactivation. Using tandem mass spectrometry, we identified two specific metabolic products of the anthracycline degradation, 3-methoxyphthalic acid and 3-methoxysalicylic acid. These two metabolic products were obtained as authentic compounds and were nontoxic to HL-60 leukemic cells and cardiac myocytes. These findings may have important implications for the cellular pharmacology of anthracyclines and for clinical oncology.

This article has been cited by other articles:

				P. Menna, E. Salvatorelli, and G. Minotti Doxorubicin Degradation in Cardiomyocytes J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 408 - 419. [Abstract] [Full Text] [PDF]

				K. J. Reszka, L. H. Britigan, and B. E. Britigan Oxidation of Anthracyclines by Peroxidase Metabolites of Salicylic Acid J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 283 - 290. [Abstract] [Full Text] [PDF]